Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L, Wetten S, O'Kelly J. Salmon JP, et al. Among authors: decosta l. Support Care Cancer. 2019 Apr;27(4):1449-1457. doi: 10.1007/s00520-018-4473-x. Epub 2018 Sep 26. Support Care Cancer. 2019. PMID: 30259136
Chemotherapy treatment patterns and neutropenia management in gastric cancer.
Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, Hendlisz A, DeCosta L, Vogl FD, Passalacqua R. Kalinka-Warzocha E, et al. Among authors: decosta l. Gastric Cancer. 2015 Apr;18(2):360-7. doi: 10.1007/s10120-014-0375-x. Epub 2014 May 5. Gastric Cancer. 2015. PMID: 24792482
Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng SL, Wong ZW, Salar A, Steger G, Abdelsalam M, DeCosta L, Szabo Z. Freyer G, et al. Among authors: decosta l. Med Oncol. 2015 Oct;32(10):236. doi: 10.1007/s12032-015-0682-z. Epub 2015 Aug 28. Med Oncol. 2015. PMID: 26315712
Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR, Bennett CW, Li S, DeCosta LJ, Jaramillo RR, Gawade PL. Schenfeld JR, et al. Among authors: decosta lj. J Oncol Pharm Pract. 2021 Jan;27(1):128-142. doi: 10.1177/1078155220915772. Epub 2020 Apr 23. J Oncol Pharm Pract. 2021. PMID: 32326872
A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Mahtani RL, Belani R, Crawford J, Dale D, DeCosta L, Gawade PL, Huynh C, Lawrence T, Lewis S, MacLaughlin WW, Narang M, Rifkin R. Mahtani RL, et al. Among authors: decosta l. Support Care Cancer. 2022 Jul;30(7):6135-6144. doi: 10.1007/s00520-022-07025-2. Epub 2022 Apr 14. Support Care Cancer. 2022. PMID: 35426046 Free PMC article.
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Rifkin RM, Crawford J, Mahtani RL, Dale DC, Narang M, MacLaughlin WW, Huynh C, Gawade PL, Lewis S, DeCosta L, Lawrence T, Belani R. Rifkin RM, et al. Among authors: decosta l. Support Care Cancer. 2022 Oct;30(10):7913-7922. doi: 10.1007/s00520-022-07226-9. Epub 2022 Jun 22. Support Care Cancer. 2022. PMID: 35732748 Free PMC article.
21 results